Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …

Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of
hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical …

Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …

Great heterogeneity in survival exists for patients newly diagnosed with diffuse large B-cell
lymphoma (DLBCL). Three scoring systems incorporating simple clinical parameters (age …

Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …

PURPOSE MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-
cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies …

Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …

Purpose Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using
a time-to-event approach with relapse, re-treatment, and death commonly used as the …

Diffuse large B-cell lymphoma (DLBCL) with MYC rearrangement (MYC-R) carries an
unfavorable outcome. We explored the prognostic value of the MYC translocation partner …

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease and represents
the most common subtype of lymphoma. Although 60–70% of all patients can be cured by …